

Identifying predictors and determining mortality rates of septic cardiomyopathy and sepsis-related cardiogenic shock: A retrospective, observational study

Kathryn W. Hendrickson<sup>1</sup>, Meghan M. Cirulis<sup>2,3</sup>, Rebecca E. Burk<sup>4</sup>, Michael J Lanspa<sup>2,3</sup>, Ithan D. Peltan<sup>2,3</sup>, Hunter Marshall<sup>3</sup>, Danielle Groat<sup>2,5</sup>, Al Jephson<sup>2,5</sup>, Sarah J. Beesley<sup>2,3</sup>, Samuel M. Brown<sup>2,3</sup>

## **AFFILIATIONS**

<sup>1</sup>The Oregon Clinic Department of Pulmonary, Critical Care, and Sleep Medicine East, Portland, OR, USA

<sup>2</sup>Division of Pulmonary and Critical Care Medicine, Intermountain Medical Center, Salt Lake City, UT, USA

<sup>3</sup>Division of Pulmonary and Critical Care Medicine, University of Utah, Salt Lake City, UT, USA

<sup>4</sup>Renown Medical Group Department of Pulmonary and Critical Care Medicine, Reno, NV, USA

<sup>5</sup>Intermountain Healthcare, Information and Analytics, Salt Lake City, UT, USA

## **Corresponding Author**

Samuel M Brown, MD, MS

Samuel.Brown@imail.org

Intermountain Medical Center

Pulmonary Division, Bldg 4, Floor 6

5121 Cottonwood St

Murray UT 84107

Phone: 801-507-4800

Fax: 801-507-4699

## Abstract

**Introduction:** Septic shock is a severe form of sepsis that has a high mortality rate, and a substantial proportion of these patients will develop cardiac dysfunction, often termed septic cardiomyopathy (SCM). Some SCM patients may develop frank cardiac failure, termed sepsis-related cardiogenic shock (SeRCS). Little is known of SeRCS. This study describes baseline characteristics of patients with SCM and SeRCS compared to patients with septic shock without cardiac dysfunction. We compare clinical outcomes among SCM, SeRCS, and septic shock, and identify risk factors for the development of SCM and SeRCS.

**Methods:** Septic patients admitted to the ICU with an echocardiogram obtained within 72 hours were included. Left ventricular ejection fraction of  $\leq 55\%$  was used to define SCM, and cardiac index  $\leq 2.1$  L/min/m<sup>2</sup> among patients with SCM defined SeRCS. Machine learning was used to identify risk factors for development of SCM and SeRCS. Logistic regression was used to compare mortality among groups.

**Results:** Among 1229 patients, 977 patients had septic shock without cardiac dysfunction, 207 had SCM, and 45 had SeRCS. In patients with septic shock, the strongest predictor for developing SCM and SeRCS was a prior history of cardiac dysfunction. Mortality did not significantly differ among the three groups.

**Conclusions:** SCM and SeRCS affect a minority of patients with septic shock, disproportionately affecting individuals with a history of cardiac disease. We did not identify a mortality difference associated with SCM or SeRCS. Additional work is needed to define further subtypes and treatment options for this patient population.

## Introduction

Sepsis is a systemic response to infection that causes organ failure and death by means of a dysregulated host response. It ranges from mild to severe, with septic shock representing the severe end of the spectrum. In the United States, sepsis is estimated to be a contributing factor or primary cause of death in up to 381,000 people annually.[1] Mortality among patients with septic shock is between 19 to 30%.[2-4]

Cardiac dysfunction in sepsis and septic shock, termed septic cardiomyopathy (SCM), is common and develops in 40–70% of adult patients depending on the definition used.[5, 6] Most prior studies examining SCM were limited by small sample size. There is also no consensus definition, but SCM is often defined as a depressed left ventricular ejection fraction (LVEF) in the context of sepsis or septic shock.[7] Depending on the definition used, SCM is a morbid condition, with mortality ranging from 14-65%.[7]

Some patients with SCM have frank cardiac failure, termed here sepsis-related cardiogenic shock (SeRCS), where the cardiac index (CI) is  $\leq 2.1$  L/min/m<sup>2</sup> despite adequate volume resuscitation. The progression from SCM to SeRCS may be a physiologic transition from a purely distributive process to a mixed shock state, with ongoing vasoplegia complicated by low cardiac output. To date, data on SeRCS are limited to case reports and case series.[8-10] Without a thorough understanding of the natural history of SeRCS, optimal treatment pathways are unclear.

We therefore sought to describe the baseline characteristics and outcomes of patients with SCM and SeRCs within a septic shock cohort, and to identify risk factors for SCM and SeRCS among patients with septic shock.

## Methods

We conducted a retrospective observational study of adult patients treated for septic shock at Intermountain Medical Center (IMC) between November 5, 2007 and July 14, 2017. IMC is a tertiary care center within an integrated healthcare system located in the Intermountain West. Although all data was de-identified, authors had access to information that could identify individual participants during or after data collection in order to complete the data analysis. IRB approval was obtained from the Intermountain Institutional Review Board.

### *Cohort Definitions*

First, eligible patients with sepsis who received vasopressors (i.e., those with septic shock) were identified via queries of the electronic data warehouse (EDW). Vasopressors were defined as norepinephrine, epinephrine, vasopressin, phenylephrine, or dopamine given 24 hours before or after admission to the ICU and sustained for  $\geq 24$  hours. We used the Rhee adaptation of SEPSIS-3 to define sepsis: receipt of antibiotics in the presence of organ dysfunction.[11, 12] Among patients who met septic shock criteria, we included those who had an echocardiogram performed within 72 hours of ICU admission, a common practice at the study hospital. Exclusion criteria included evidence of obstructive or hemorrhagic shock, presence of ST segment myocardial infarction (STEMI), or admission for organ donation. Presence of hemorrhagic and obstructive shock were determined by manual chart review of patient records.

Among patients with septic shock, we identified patients with SCM defined as an LVEF  $\leq 55\%$ . If a patient previously had a low LVEF ( $< 55\%$ ), SCM was defined as a decrease in LVEF of  $\geq 10\%$  (absolute) from baseline. Among patients meeting criteria for SCM, SeRCS was defined as patients with SCM who had at least one CI  $\leq 2.1$  L/min/m<sup>2</sup> as measured by echocardiogram.

### *Data Extraction*

Data related to the septic shock, SCM, and SeRCS cohorts were manually gathered from medical charts and entered into REDCap.[13, 14] Demographic, clinical, laboratory, and treatment data for this study were obtained from the Intermountain Health EDW via queries.[15] Race and ethnicity were self-reported: non-Hispanic/Latino Black, Hispanic/Latino, non-Hispanic/Latino white, and Other. All labs and therapies were measured within the first 24 hours the patient met septic shock criteria. An indicator for high and/or low values was used for hemoglobin, platelet count, white blood cell count, and troponin. The LVEF (Simpson's method of discs) and CI were calculated by a critical care echocardiogram board-certified physician reader. The CI was calculated using the left ventricular outflow tract velocity time interval (LVOT-VTI) method.[16] The site of infection was defined by discharge ICD-10 codes.

All-cause mortality was defined at hospital discharge, 30 -days, and 90 -days, using the EDW, Utah State death records, and the Social Security Death Index.

### *Comparison of baseline characteristics*

Descriptive statistics were used to describe the prevalence and baseline characteristics of SeRCS, SCM, and septic shock within the overall cohort. Data are reported as median, (interquartile range), or count (percent) unless specified otherwise.

### *Mortality analysis*

Multivariable logistic regression was used to compare all-cause in-hospital mortality among the three subgroups. Predefined covariates included age, sex, race/ethnicity, highest SOFA score within the first 24 hours of ICU admission, Elixhauser Comorbidity Index using the Thompson 30 Index[17], highest norepinephrine equivalent (NEE) infusion rate within the first 24 hours of

ICU admission, and receipt of mechanical ventilation at any time after ICU admission. Due to the exploratory nature of the analysis, we did not adjust for the multiple comparisons.

Significance was set to  $p < 0.05$ .

### *Risk factor identification for SCM and SeRCS*

We evaluated risk factors for both SCM and SeRCS among patients with septic shock. Features that were used for diagnostic purposes (e.g., LVEF and CI), and treatments and labs directly related to diagnosis (e.g. missingness of troponin was not at random) were not included in the modeling process. We took a 3-step approach to identify risk factors: 1) split data set into training and testing, 2) feature selection, and 3) model selection. Here we describe the data analysis pipeline for risk factor identification of SCM within the septic shock cohort. A similar approach was used for SeRCS risk factors compared to the septic shock cohort, and differences are described below.

Prior to splitting the datasets, we used cut-off values to define abnormality of several lab results. (Supplemental Table 1)

Next, the SCM and septic shock dataset was split at random for training (60%) and testing (40%) to create 100 versions of the data. In the feature selection step, the training data was prepared by normalizing continuous variables while categorical variables were encoded a binary variable for each unique category (i.e., one-hot coding). Three algorithms were applied to the training datasets, univariate logistic regression (LR), Random Forest (RF), and XGBoost (XGB).[18, 19] For the RF analysis we turned three different hyperparameters: number of trees to grow, number of variables randomly sampled at each split, and minimum size of terminal nodes, in a grid-search fashion of 3 settings per hyperparameter for a total of nine models. Likewise, a total of

nine XGBoost models were built with three settings for three hyperparameters: step size of each boosting step, maximum tree depth, and number of iterations.

P-values from univariate LR were used to order the features from lowest p-value to highest. RF features were ranked using the Gini score, or the mean decrease in accuracy if the feature is dropped from the tree. XGBoost used gain to set feature precedence, the average gain in accuracy across splits where the feature was used. Lists of features from the resulting models were created as ordered lists. In the case of predicting SCM from septic shock, the size of the feature list included up to 30 features while predicting SeRCS from septic shock included up to 10 features. Fewer features were used for SeRCS due to the limited number of observations for evaluation. The most commonly occurring feature set combination in the feature selection process was identified.

In the model selection step, each list of features and the test data were included in a multivariate logistic regression model. The best performing model with respect to the area under the curve (AUC) of the receiver operating characteristics curve (ROC) were presented as the prediction model for differentiating SCM or SeRCS. Additional metrics were reported on the best performing model, including accuracy, sensitivity, and specificity. Odds ratios were calculated for the best model and used to quantify the level of risk for the identified features. The best model was calibrated and provided a full report of its parameters for its potential use as a prediction model.

All analyses were conducted with R version 4.0.2.[20]

## **Results**



### Baseline characteristics

The initial query identified patients with septic shock and echocardiogram performed within 72 hours of admission during the study time frame. Exclusion criteria and data missingness required for diagnostic purposes excluded approximately 3,400 patients. We included 1229 patients with septic shock in this study, of which 977 (79%) had no SCM, 207 (17%) had SCM alone, and 45 (4%) had SCM with SeRCS. (Figure 1) Compared to patients with septic shock alone, patients with SCM alone or SCM with SeRCS were similar age (63.0 [IQR 53.0-73.0]) vs 65.0 [IQR 52.0-76.5] vs 69.0 [IQR 53.0-76.0] but were less likely to be female (54% vs 42.0% vs 31.1%). SCM alone and SeRCS patients also had higher Elixhauser comorbidity scores (29.0 [IQR 18.0-41.0] vs 30.0 [IQR 19.0-44.0] vs 35.0 [IQR 25.0-47.0]) and more preexisting congestive heart failure (CHF) (35.4% vs 76.8% vs 93.3%). Mean LVEF was lower for SCM alone and SeRCS (65.0% [IQR 55.0-70.0%] vs 35.0% [IQR 26.5-41.5%] vs 27.0% [IQR 18.0-35.0%]). Inotropes (dobutamine or milrinone) were administered to 19.1% of patients with septic shock, 38.6% of patients with SCM alone, and 46.7% of patients with SeRCS. (Table 1) Additional baseline laboratory results are presented in Supplemental Tables 2 and 3.

**Table 1:** Patient demographics and baseline characteristics. All data reported as median (interquartile range) or n(%) unless specified otherwise.

Characteristic	Septic Shock without SCM	Septic Cardiomyopathy without SeRCS	SeRCS
	n=977	n=207	n=45
Age, years	63.0 (53.0-73.0)	65.0 (52.0-76.5)	69.0 (53.0-76.0)
Female	528 (54.0%)	87 (42.0%)	14 (31.1%)
Race/Ethnicity			
Non-Hispanic/Latino			
Black	6 (0.6%)	1 (0.5%)	1 (2.2%)
Hispanic/Latino	11 (1.1%)	0 (0.0%)	0 (0.0%)

Non-Hispanic/Latino white	851 (87.1%)	179 (86.5%)	41 (91.1%)
Other	109 (11.2%)	27 (13.0%)	3 (6.7%)
Body mass index (kg/m)	29.0 (23.9-35.9)	26.6 (22.9-31.4)	28.9 (22.7-35.4)
Comorbidity Scores			
Elixhauser Score	29.0 (18.0-41.0)	30.0 (19.0-44.0)	35.0 (25.0-47.0)
APACHE II Score	31.0 (24.0-39.0)	31.0 (25.0-41.0)	32.0 (25.0-41.0)
SOFA Score	9.0 (7.0-11.0)	9.0 (7.0-11.0)	9.0 (7.0-12.0)
History of coronary artery disease	386 (39.5%)	119 (57.5%)	37 (82.2%)
Pacemaker	24 (2.5%)	11 (5.3%)	7 (15.6%)
Beta-blocker use	148 (15.1%)	31 (15.0%)	24 (53.3%)
Blood Chemistries			
Creatinine	1.8 (1.1-3.1)	1.7 (1.1-2.6)	1.8 (1.3-3.0)
Abnormal troponin	623 (63.8%)	167 (80.7%)	39 (86.7%)
Abnormal BNP	343 (35.1%)	92 (44.4%)	28 (62.2%)
High WBC	536 (54.9%)	97 (46.9%)	30 (66.7%)
Low WBC	196 (20.1%)	55 (26.6%)	7 (15.6%)
High hemoglobin	42 (4.3%)	6 (2.9%)	3 (6.7%)
Low hemoglobin	564 (57.7%)	104 (50.2%)	24 (53.3%)
High platelet	75 (7.7%)	8 (3.9%)	2 (4.4%)
Low platelet	354 (36.2%)	67 (32.4%)	16 (35.6%)
Lowest pH	5.5 (5.0-6.0)	5.5 (5.0-6.0)	5.5 (5.0-7.0)
Highest norepinephrine equivalent rate (24 hours)	0.2 (0.1-0.5)	0.3 (0.1-0.6)	0.3 (0.1-0.9)
Total norepinephrine equivalent administered (24 hours) (mcg/kg/min)	2.3 (0.4-8.7)	2.8 (0.5-8.4)	2.4 (0.3-6.1)
Mechanically ventilated	574 (58.8%)	129 (62.3%)	28 (62.2%)
Site of Infection			
Pulmonary	75 (7.7%)	17 (8.2%)	8 (17.8%)
Urinary	256 (26.2%)	40 (19.3%)	7 (15.6%)
Abdominal	83 (8.5%)	17 (8.2%)	2 (4.4%)
Skin and soft tissue	31 (3.2%)	2 (1.0%)	2 (4.4%)
Central nervous system	8 (0.8%)	0 (0.0%)	0 (0.0%)
Bloodstream	11 (1.1%)	5 (2.4%)	0 (0.0%)

### *Mortality*

The all-cause in-hospital mortality rate for those with septic shock, SCM, and SeRCS was 386 (39.5%), 92 (44.4%), and 18 (40.0%) respectively. Mortality rates for 30-day, 90-day, and 1-year mortality followed a similar pattern within the SeRCS group. (Table 2)

**Table 2:** Mortality outcomes across subgroups.

Timepoint	Septic Shock n=977	Septic Cardiomyopathy n=207	SeRCS n=45	Overall n=1229
All-cause in-hospital	386 (39.5%)	92 (44.4%)	18 (40.0%)	496 (40.4%)
30-day	429 (43.9%)	96 (46.4%)	22 (48.9%)	547 (44.5%)
90-day	484 (49.5%)	107 (51.7%)	24 (53.3%)	615 (50.0%)
1-year	533 (54.6%)	120 (58.0%)	25 (55.6%)	678 (55.2%)

After controlling for relevant covariates, the presence of SCM (adjusted odds ratio [aOR] 1.27, 95% CI 0.91-1.76) or SeRCS (aOR 0.86, 95% CI 0.43-1.66) was not associated with increased in-hospital mortality compared to septic shock without SCM. Similarly, neither SCM or SeRCS were associated with increased risk-adjusted 30-days, 90-days, and 1-year mortality. (Table 3)

**Table 3:** Adjusted odds ratio (95% confidence interval) for mortality at different time points for septic cardiomyopathy (SCM) and sepsis-related cardiogenic shock (SeRCS) compared to septic shock without SCM.

Timepoint	Odds Ratio (95% CI)	p-value
All-cause in-hospital mortality		
SCM	1.27 (0.91-1.76)	0.160
SeRCS	0.86 (0.43-1.66)	0.650
30-day Mortality		
SCM	1.12 (0.8-1.55)	0.520
SeRCS	1.01 (0.52-1.96)	0.980
90-day Mortality		
SCM	1.08 (0.78-1.5)	0.650
SeRCS	0.92 (0.47-1.81)	0.810
1-year Mortality		
SCM	1.15 (0.82-1.61)	0.419
SeRCS	0.81 (0.41-1.59)	0.527

### *Identification of risk factors*

The data analysis pipeline and machine learning algorithm (Figure 2) found the best performing features for predicting SCM were history of congestive heart failure (CHF), abnormal troponin, and male sex. (Table 4, Supplemental Table 4) This model achieved an average AUC-ROC of 0.77. Logistic regression features and their coefficients are reported in Table 4.

**Table 4:** Odds ratios and log odds coefficients from the best performing models to predict septic cardiomyopathy (SCM) and sepsis-related cardiogenic shock (SeRCS) within a cohort of patients with septic shock.

Feature	Odds Ratio	Log Odds	Threshold
SCM			0.1293
Intercept	-	-3.234	
History of CHF	4.07	1.40	
Abnormal troponin	2.30	0.83	
Male	1.63	0.49	
SeRCS			0.0779 – 0.1329
Intercept	-	-5.367	
History of CHF	8.87	2.18	
History of valvular disease	2.02	0.70	
History of coronary artery disease	1.95	0.67	
History of peripheral vascular disorders	1.90	0.64	

The best performing model for SeRCS included history of CHF, history of valvular disease, history of coronary artery disease, and history of peripheral vascular disorders. The only other feature that occurred frequently but was not included in the final model was presence of a pacemaker. (Table 4, Supplemental Table 4) The average AUC-ROC for the best performing model was 0.91. The accuracy was 0.85 with sensitivity and specificity maximized at 0.85 and

0.85, respectively. Feature coefficients from the logistic regression model are reported in Table 4.

In a post hoc analysis, we explored the natural history of SeRCS among the 3 patients with no prior history of cardiac dysfunction. Patient 1 was an intravenous (IV) drug user with tricuspid valve endocarditis, severe tricuspid regurgitation, and RV overload and failure. The patient had a history of coarctation of the aorta and bicuspid aortic valve with repair. One year prior to this admission he was admitted with tricuspid valve endocarditis with annuloplasty and completion of a full course of antibiotics. Echocardiogram before endocarditis confirmed LV valve function. He expired soon after admission to the ICU. Patient 2 had a history of coronary artery bypass grafting and stent placement in the coronary arteries, but no evidence in the HER to suggest heart failure or reduced LVEF. Patient 3 had end-stage liver disease and was admitted with empyema and septic shock. Echocardiogram three months prior to admission was unremarkable, while admission echocardiogram showed decreased LV and RV systolic function as well as new regional wall motion abnormalities. The patient expired soon after admission the ICU. Whether the regional wall motion abnormalities suggest obstructive coronary disease is unknown.

## **Discussion**

In this large, single-center cohort study we describe for the first time the epidemiology of SeRCS. SeRCS appears to be overwhelmingly the syndrome of septic shock in a subset of patients with preexisting severe cardiac disease. These patients have similar outcomes, in the contemporary clinical environment (which commonly includes inotrope therapy), as patients with septic shock with or without SCM. A very small group of patients with SeRCS and no

apparent preexisting cardiac dysfunction were identified, although in each case cardiac dysfunction independent of sepsis was a distinct possibility.

All risk factors for SeRCS identified in this cohort study related to prior cardiac history.

Biomarkers associated with SeRCS include elevated troponin and elevated BNP, traditional markers of cardiac dysfunction.

Our study showed a lower rate of SCM compared to previous studies. This is likely due to two factors. First, our cohort is larger than prior cohorts and benefits from a common clinical practice in the study hospital of performing echocardiography in patients with shock, including septic shock. Second, we used a simple LVEF-based definition of SCM, whereas definition based in longitudinal strain may identify more patients with subtler cardiac dysfunction. Our results may thus better reflect a real-world population.

Similar to our study, previous studies of SCM based on LVEF measurements suggest that these patients did not have higher mortality than septic shock patients.[8, 21] Different definitions of SCM have been associated with different estimates of attributable mortality.[22-25] We chose the readily available and reproducible LVEF. We considered the possibility that inotrope therapy may have masked mortality differences, but septic shock patients with normal cardiac function received inotrope therapy at roughly similar rates to SCM and SeRCS patients (reflecting the then-common practice of goal-directed hemodynamic therapy in septic shock).

Similar to previous cohorts with SCM[7, 22], male patients with prior cardiovascular disease are most at risk for developing both SCM and SeRCS.

This, the largest study of SeRCS to date, lays the groundwork for future investigations into the optimal definition of sub-populations and treatment strategies for patients experiencing

cardiogenic shock in the setting of septic shock. A limitation of this study was that it is single centered with a relatively small number of SeRCS patients. This definition may over-simplify SCM, as diastolic and right ventricular (RV) dysfunction have also been identified as components of the SCM syndrome.[26, 27] SeRCS in patients without prior cardiac disease appears extremely rare in this cohort; defining epidemiology, natural history, and optimal treatment strategies in this group will require large-scale, multi-center collaborations.

## **Conclusion**

This study is the first to describe patients with SeRCS from a large cohort of ICU patients with septic shock. SeRCS patients largely have preexisting cardiac disease which deteriorates in the setting of septic shock. The patients with SeRCS have similar outcomes, even when treated with goal-directed hemodynamic therapy, as patients with SCM or septic shock alone. Other important risk factors for development of SCM with and without SeRCS are history of cardiovascular disease and male sex. Further study in this area is needed to clearly define SCM with and without SeRCS, and to delineate optimal treatments for this group of patients.


## References

1. Epstein, L., et al., *Varying Estimates of Sepsis Mortality Using Death Certificates and Administrative Codes--United States, 1999-2014*. MMWR Morb Mortal Wkly Rep, 2016. **65**(13): p. 342-5.
2. Investigators, A., et al., *Goal-directed resuscitation for patients with early septic shock*. N Engl J Med, 2014. **371**(16): p. 1496-506.
3. Mouncey, P.R., G.S. Power, and T.J. Coats, *Early, Goal-Directed Resuscitation for Septic Shock*. N Engl J Med, 2015. **373**(6): p. 577-8.
4. Pro, C.I., et al., *A randomized trial of protocol-based care for early septic shock*. N Engl J Med, 2014. **370**(18): p. 1683-93.
5. Pulido, J.N., et al., *Clinical spectrum, frequency, and significance of myocardial dysfunction in severe sepsis and septic shock*. Mayo Clin Proc, 2012. **87**(7): p. 620-8.
6. Sato, R. and M. Nasu, *A review of sepsis-induced cardiomyopathy*. J Intensive Care, 2015. **3**: p. 48.
7. Beesley, S.J., et al., *Septic Cardiomyopathy*. Crit Care Med, 2018. **46**(4): p. 625-634.
8. Parker, M.M., et al., *Profound but reversible myocardial depression in patients with septic shock*. Ann Intern Med, 1984. **100**(4): p. 483-90.
9. Jardin, F., et al., *Sepsis-related cardiogenic shock*. Crit Care Med, 1990. **18**(10): p. 1055-60.
10. Weil, M.H. and H. Nishijima, *Cardiac output in bacterial shock*. Am J Med, 1978. **64**(6): p. 920-2.




11. Rhee, C., et al., *Incidence and Trends of Sepsis in US Hospitals Using Clinical vs Claims Data, 2009-2014*. JAMA, 2017. **318**(13): p. 1241-1249.
12. Singer, M., et al., *The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)*. JAMA, 2016. **315**(8): p. 801-10.
13. Harris, P.A., et al., *The REDCap consortium: Building an international community of software platform partners*. J Biomed Inform, 2019. **95**: p. 103208.
14. Harris, P.A., et al., *Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support*. J Biomed Inform, 2009. **42**(2): p. 377-81.
15. Clayton, P.D., et al., *Building a comprehensive clinical information system from components. The approach at Intermountain Health Care*. Methods Inf Med, 2003. **42**(1): p. 1-7.
16. Blanco, P., *Rationale for using the velocity-time integral and the minute distance for assessing the stroke volume and cardiac output in point-of-care settings*. Ultrasound J, 2020. **12**(1): p. 21.
17. Thompson, N.R., et al., *A new Elixhauser-based comorbidity summary measure to predict in-hospital mortality*. Med Care, 2015. **53**(4): p. 374-9.
18. Breiman, L., *Random Forests*. Machine Learning, 2001. **45**: p. 5-32.
19. Chen, T., Guestrin, Carlos, *XGBoost: A Scalable Tree Boosting System*. KDD '16, August 13-17, 2016, 2016: p. 785-794.
20. Team, T.R.C. *The R Project for Statistical Computing*. 2020 [11/18/2022]; Available from: <https://www.r-project.org/>.

21. Huang, S.J., M. Nalos, and A.S. McLean, *Is early ventricular dysfunction or dilatation associated with lower mortality rate in adult severe sepsis and septic shock? A meta-analysis*. Crit Care, 2013. **17**(3): p. R96.
22. Beesley, S.J., et al., *Long-Term Implications of Abnormal Left Ventricular Strain During Sepsis*. Crit Care Med, 2021. **49**(4): p. e444-e453.
23. Vallabhajosyula, S., et al., *New-Onset Heart Failure and Mortality in Hospital Survivors of Sepsis-Related Left Ventricular Dysfunction*. Shock, 2018. **49**(2): p. 144-149.
24. Yende, S., et al., *Risk of cardiovascular events in survivors of severe sepsis*. Am J Respir Crit Care Med, 2014. **189**(9): p. 1065-74.
25. Sanfilippo, F., et al., *Left ventricular systolic function evaluated by strain echocardiography and relationship with mortality in patients with severe sepsis or septic shock: a systematic review and meta-analysis*. Crit Care, 2018. **22**(1): p. 183.
26. Brown, S.M., et al., *Diastolic dysfunction and mortality in early severe sepsis and septic shock: a prospective, observational echocardiography study*. Crit Ultrasound J, 2012. **4**(1): p. 8.
27. Lanspa, M.J., et al., *Right Ventricular Dysfunction in Early Sepsis and Septic Shock*. Chest, 2021. **159**(3): p. 1055-1063.



medRxiv preprint doi: <https://doi.org/10.1101/2023.08.19.23294310>; this version posted August 21, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

**Figure 1: Flow of patients into the study cohort.**



medRxiv preprint doi: <https://doi.org/10.1101/2023.08.10.23294310>; this version posted August 12, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

**Figure 2:** Data analysis pipeline and machine learning algorithms to identify risk factors for development of SCM and SeRCS.